Literature DB >> 16824619

Sarcolemma-specific autoantibodies in canine inflammatory myopathy.

Sabine Hankel1, G Diane Shelton, Eva Engvall.   

Abstract

Inflammatory myopathies (IM) are relatively common in dogs with an increased incidence in the Boxer and Newfoundland breeds. Here, we show that a high proportion of affected Boxers and Newfoundlands have circulating autoantibodies against unknown sarcolemma antigens, that are muscle-specific but not species specific. We further show that the autoantigen can be extracted from muscle membranes with non-ionic detergent, and that such detergent extracts can be used in a sensitive ELISA for detection and quantitation of antibodies. The relatively high incidence of IM with autoantibodies in selected breeds of dogs indicates a genetic predisposition for a particular form of IM. In these breeds, this form of IM could be diagnosed and monitored with a simple serum assay.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16824619     DOI: 10.1016/j.vetimm.2006.03.025

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  3 in total

1.  Leishmania spp.-Infected Dogs Have Circulating Anti-Skeletal Muscle Autoantibodies Recognizing SERCA1.

Authors:  Francesco Prisco; Davide De Biase; Giuseppe Piegari; Francesco Oriente; Ilaria Cimmino; Valeria De Pasquale; Michele Costanzo; Pasquale Santoro; Manuela Gizzarelli; Serenella Papparella; Orlando Paciello
Journal:  Pathogens       Date:  2021-04-12

Review 2.  A scoping review of autoantibodies as biomarkers for canine autoimmune disease.

Authors:  Amy E Treeful; Emily L Coffey; Steven G Friedenberg
Journal:  J Vet Intern Med       Date:  2022-02-22       Impact factor: 3.333

3.  Association of an MHC class II haplotype with increased risk of polymyositis in Hungarian Vizsla dogs.

Authors:  Jonathan Massey; Simon Rothwell; Clare Rusbridge; Anna Tauro; Diane Addicott; Hector Chinoy; Robert G Cooper; William E R Ollier; Lorna J Kennedy
Journal:  PLoS One       Date:  2013-02-14       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.